Palladone

Quick links to important sections

Palladone

Selected form

Method of action: Analgesic

Treatment option: Pain, Cancer

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Palladone

What is Palladone? Defining the Core Medication

Property Description
Active ingredient Hydromorphone Hydrochloride
Form Oral capsules (Extended/Immediate-release), Tablets, Solution, Injection
Pharmacological class Opioid Analgesic, mu-Opioid Receptor Agonist
General purpose Management of moderate-to-severe pain
Origin Semi-synthetic (derivative of Morphine)

Palladone is a recognized brand name for the prescription medication whose primary active ingredient is Hydromorphone Hydrochloride, a potent semi-synthetic opioid analgesic. This medication is fundamentally classified as a pure mu-opioid receptor agonist, positioning it within the powerful category of drugs derived from the natural opium alkaloid, morphine. Hydromorphone is used to relieve moderate-to-severe pain that lasts for more than a few days, particularly in the management of serious, persistent discomfort.


Composition, Origin, and Available Forms

Hydromorphone Hydrochloride is typically formulated as a single-ingredient product, containing only the active compound and necessary pharmaceutical excipients. Palladone is specifically recognized for its extended-release oral capsules, a differentiating feature that provides sustained delivery of the active ingredient over time. The active ingredient is also widely available in other high-level dosage form(s), including immediate-release oral tablets, an oral solution, and sterile injectable solutions. As an opioid agonist, Hydromorphone works by changing the way the brain and nervous system respond to pain. This versatility in forms allows for the medicine to be delivered via the oral route for sustained or immediate relief, as well as the parenteral routes (intravenous, subcutaneous, or intramuscular) in clinical settings.


The General Purpose of This Powerful Analgesic

The overarching purpose of Palladone is to provide effective analgesia, which is the relief of pain, by acting directly on the central nervous system. Its primary therapeutic benefit is the management of moderate-to-severe pain in cases such as persistent discomfort following a major surgical procedure or long-term severe chronic pain where relief cannot be achieved using non-opioid medications. The high potency of the drug ensures that it remains an option for severe pain management.

Regulatory References

  1. Hydromorphone - StatPearls - NCBI Bookshelf - NIH
  2. opioid analgesic
  3. management of moderate-to-severe pain
  4. oral tablets
  5. oral solution

What side effects are possible with Palladone?

Palladone (hydromorphone extended-release) is a potent opioid pain reliever that carries significant risks, including addiction, abuse, and misuse, which can lead to overdose and death. It should only be used by patients who are already opioid-tolerant and requires careful prescribing and monitoring.

Serious Side Effects

Life-threatening respiratory depression is the most significant risk. This can occur, especially during the start of therapy or following a dose increase. Symptoms include slowed breathing, shallow breathing, and long pauses between breaths, which require immediate emergency medical attention. The extended-release capsule must be swallowed whole, as crushing, chewing, or dissolving it can cause rapid release of a fatal dose of hydromorphone.

Other serious risks include: Serotonin Syndrome (agitation, hallucinations, fever, fast heartbeat), Adrenal Insufficiency (nausea, vomiting, loss of appetite, weakness), and severe Allergic Reactions (rash, hives, swelling of the face, throat).

Common Side Effects

As with most opioids, common side effects are generally related to the central nervous and gastrointestinal systems. They include:

Body System
Gastrointestinal Constipation, Nausea, Vomiting, Dry mouth
Nervous System Dizziness, Headache, Drowsiness (Somnolence)
Other Itching (Pruritus), Sweating, Weakness (Asthenia)

Constipation is particularly common and may require proactive management with laxatives as directed by a healthcare provider.

Safety Information

Prolonged use during pregnancy may cause Neonatal Opioid Withdrawal Syndrome in the newborn. Concurrent use with alcohol or other central nervous system depressants (e.g., benzodiazepines) should be avoided as it can greatly increase the risk of profound sedation, respiratory depression, coma, and death.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

Overdose Scope

Feature Official Regulatory Documentation Statement
Documented Overdose Presentations Symptoms include respiratory depression (chief hazard), profound sedation progressing to stupor or coma, constricted pupils (miosis), cold and clammy skin, hypotension, and bradycardia.
Physiological Systems Affected Central Nervous System (CNS), Respiratory system (leading to apnea), Cardiovascular system, Skeletal muscle (flaccidity).
Dose-Related Factors Risk is associated with doses higher than recommended and accidental ingestion, particularly by children.
Population-Specific Overdose Notes Elderly, debilitated patients, and those with chronic pulmonary disease are at increased risk for life-threatening respiratory depression in an overdose scenario.
Emergency-Response Statements Seek immediate medical treatment/help right away. Call 911 immediately (or local emergency services).
When Immediate Medical Help Is Required Urgent help is required when signs include slowed breathing, long pauses between breaths (apnea), or inability to respond or wake up.

Official Overdose Statements:

  • The primary hazard of an acute overdose is severe respiratory depression that may progress to apnea and lead to death.
  • Circulatory collapse is a documented severe outcome, and symptomatic management must include supportive measures such as assisted ventilation.
  • The specific antidote for reversing acute respiratory depression is Naloxone, which may require repeat doses due to the potential for symptom relapse.

The regulatory profile emphasizes that the most severe presentations are life-threatening and require immediate professional intervention. The documented signs of CNS depression and breathing problems serve as the official triggers for calling 911 and initiating a response that includes supportive measures and the administration of an opioid antagonist.

Therapeutic Uses of Palladone

Palladone (Hydromorphone) is an opioid analgesic used for symptoms of severe pain that require daily, long-term treatment. It is used for the management of pain that is severe enough to require around-the-clock, long-term treatment when alternative treatment options are inadequate. This is commonly used across conditions characterized by periods of heightened symptoms and significant physiological strain.


The common therapeutic focus of this medication is severe, persistent pain which may be unresponsive to other pain management approaches. This includes pain associated with cancer or other progressive diseases, and severe discomfort following a major surgical procedure. The medication is also relevant for symptom management in palliative care settings. This therapeutic approach provides support that helps ease the overall symptom burden for patients.

The use in these contexts assists with maintaining functional stability and contributes to supporting comfort and stability during phases of heightened, acute discomfort.

A key therapeutic benefit is offering symptomatic relief that helps patients cope more steadily with severe symptom fluctuations.


Quick Fact: Relief for Refractory Pain

Quick Fact: Relief for Refractory Pain

The medication is typically considered when pain symptoms are unresponsive to standard non-opioid medications, helping to address symptom clusters that may become intense or disruptive.

Eligibility and Restrictions for Use

Eligibility Scope

Palladone (hydromorphone) is officially reserved for opioid-tolerant patients who require continuous, around-the-clock, long-term opioid treatment. This restricted scope is a core regulatory constraint.

Populations for Whom Use is Contraindicated

Official labeling mandates that the medicine must not be used in individuals with specific high-risk conditions, classifying them as absolute contraindications:

  • Opioid Non-Tolerant Patients: Use in this group is prohibited for extended-release forms due to the high risk of fatal respiratory depression.
  • Severe Respiratory Conditions: Patients with significant respiratory depression or acute/severe bronchial asthma.
  • Gastrointestinal Obstruction: Individuals with known or suspected paralytic ileus or other GI tract obstructions.
  • MAOI Use: Patients currently taking or having stopped Monoamine Oxidase Inhibitors (MAOIs) within the past 14 days.

Condition-Specific and Age-Related Eligibility

Category Regulatory Status
Hepatic/Renal Impairment Restricted use; patients with moderate impairment require a reduced initial dose. Severe impairment may require an alternate analgesic.
Pediatric Patients (<18) Safety and effectiveness have not been established; use is not recommended.
Pregnancy and Lactation Not recommended. Prolonged use during pregnancy may result in Neonatal Opioid Withdrawal Syndrome.

Connection to the overall eligibility profile Regulatory documents strictly define the eligible population by requiring prior opioid tolerance and establishing formal exclusions based on compromised respiratory, gastrointestinal, or organ function. This structure reflects a high-risk classification that mandates caution beyond standard adult use.

What should I know about interactions with other medicines?

Concomitant use of Palladone (hydromorphone extended-release) with certain other medicines and products is associated with serious documented risks, leading to strict regulatory requirements and constraints.

Documented Interaction Categories

Interacting Product Category Official Constraint/Implication
Alcohol (Ethanol) Prohibited. Co-ingestion is strictly forbidden due to the risk of uncontrolled, rapid release of hydromorphone (dose-dumping), which can cause a potentially fatal overdose even in opioid-tolerant patients.
CNS Depressants (e.g., sedatives, hypnotics, other opioids, tranquilizers, general anesthetics, gabapentinoids [gabapentin, pregabalin]) Dose Adjustment/Monitoring. Combination use may result in profound sedation, respiratory depression, coma, and death due to additive effects. If co-administration is necessary, the dose of one or both agents must be reduced and the patient closely monitored.
Monoamine Oxidase Inhibitors (MAOIs) Avoidance Period. Should not be used in patients taking an MAOI or within 14 days of stopping treatment with an MAOI, as MAOIs can potentiate the effects of hydromorphone.
Mixed Agonist/Antagonist Opioid Analgesics (e.g., pentazocine, butorphanol, nalbuphine, buprenorphine) Avoidance. Co-administration may reduce the pain-relieving effect of Palladone and/or precipitate opioid withdrawal symptoms.
Anticholinergic Drugs Monitoring. Concomitant use increases the risk of severe constipation or urinary retention, which may progress to paralytic ileus.

Mechanism of Action

Palladone (hydromorphone) acts at a molecular level to modulate central nervous system (CNS) signaling pathways. This is primarily achieved through high-affinity binding to specific receptor targets, initiating a cascade of intracellular events.


Opioid Receptor Signaling Modulation

This domain covers the drug’s primary action: its role as an agonist at mu-opioid receptors (mu-OR), which are dense throughout the brain and spinal cord. Binding to mu-ORs activates an inhibitory G-protein cascade, which suppresses the electrical excitability of neurons. The physiological consequence is a reduction in the excitability and signal transmission across targeted neurons.


Neuronal Membrane Ion Flux Regulation

Within the signaling cascade, the drug modifies early molecular steps by influencing ion movement across the neuronal membrane. mu-OR activation leads to an increase in potassium ion conductance (hyperpolarizing the neuron) and a decrease in calcium ion influx at the presynaptic terminal. This dual effect limits the release of excitatory neurotransmitters (like glutamate). This action modulates neuronal firing patterns and induces distinct physiological shifts within the CNS.

Dosage and Administration Information

How to Use Palladone: Administration Principles

Palladone (Hydromorphone) is a scheduled medication whose use is characterized by specific administration routes and dosing protocols. The medication is administered via the oral route (as extended-release capsules or tablets) or the parenteral routes, specifically intravenous (i.v.) and subcutaneous (s.c.), using the solution form.

Extended-release products are intended only for opioid-tolerant patients requiring around-the-clock, long-term management and are not for use as an as-needed analgesic. The dosing regimen for extended-release forms requires once-daily administration (every 24 hours). For adjustment, the dose is increased gradually, typically using increments of 4 to 8 mg every three to four days until stable dosing is achieved. Immediate-release formulations, conversely, are typically administered at 4-hourly intervals.

Administration mandates strict form-specific handling: extended-release capsules and tablets must be swallowed whole and must not be crushed, chewed, or split. However, the contents of the immediate-release capsules may be opened and sprinkled onto cold soft food. Standard administration parameters specify that use in children under 12 years is generally not recommended, and a reduced initial dose is required for patients with moderate renal or hepatic impairment. Long-term use necessitates a gradual dose taper upon discontinuation rather than abrupt cessation.

Recent Clinical Evidence

Research evidence / Overview of studies for Palladone


Evidence for use in Chronic Moderate-to-Severe Pain

The clinical evaluation for Palladone (Hydromorphone Extended-Release) has included short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time and were applied in research contexts involving fluctuating or unstable symptoms. The trials compared the medication against a placebo and involved randomized withdrawal studies to evaluate the consistency of pain management over a defined time interval.

Researchers monitored outcomes related to physical discomfort, specifically by measuring weekly mean pain intensity scores and evaluating the maintenance of analgesia. The available evidence for the short-term comparison of the study agent against placebo in the opioid-tolerant population is typically classified as high-certainty data.


Research Comparing Hydromorphone to Other Opioids

Research has also explored the active ingredient, hydromorphone, in study settings involving severe pain, such as that associated with cancer. These were mainly active-control RCTs that evaluated hydromorphone relative to other common opioid medications (like morphine or fentanyl). Findings from systematic reviews indicate low certainty regarding any specific difference in pain measurements observed between hydromorphone and the other studied opioid medications.


What Remains Unclear About the Evidence

One key gap is the limited information for long-term outcomes. The controlled follow-up durations were typically limited to a few weeks to a few months, meaning that data for long-term effects are not fully established. Furthermore, while the core efficacy data for short-term use in opioid-tolerant adults is established, comparative evidence remains limited for many head-to-head comparisons against other opioids, and subgroup findings are uncertain for many non-adult groups.

Key Studies & References

  1. Hydromorphone: MedlinePlus Drug Information (General Context and Patient Information)
  2. Hydromorphone (StatPearls - NCBI Bookshelf) (Systematic Evidence Review)

Frequently Asked Questions (FAQ)

Common questions about Palladone (FAQ)


Q: Does Palladone contain codeine?

The active ingredient in Palladone is hydromorphone hydrochloride. Official product labeling describes it as a single-ingredient medicine that is a derivative of morphine. The official ingredient list does not include codeine.


Q: Why is Palladone classified as a Schedule II substance?

Regulatory documents classify hydromorphone, the active ingredient in Palladone, as a Schedule II controlled substance. This classification indicates that the drug has a high potential for abuse. Use may lead to severe psychological or physical dependence, which necessitates strict controls on prescribing and dispensing.


Q: How quickly does Palladone start to work after taking it?

The time it takes for Palladone to start working depends on the formulation. Immediate-release oral medicines typically begin to relieve pain in about 15 to 30 minutes. The extended-release forms are designed for around-the-clock pain management and have a significantly delayed onset, generally taking about six hours to reach effective concentrations.


Q: Do certain foods affect how Palladone works?

Official administration guidelines for the immediate-release capsule state that its contents may be opened and sprinkled onto a small amount of cold soft food. Beyond this specific instruction, the official product information does not typically note other particular food interactions. Co-ingestion with alcohol is strictly prohibited in regulatory documents due to the risk of a potentially fatal overdose.


Q: Are there any herbal supplements that interact with Palladone?

Yes, there are some nonprescription and herbal products known to interact with the active ingredient, hydromorphone. According to authoritative drug information, certain supplements like St. John's wort and tryptophan may affect how the medicine works in the body. Official guidance emphasizes the need to inform a healthcare provider of all supplements and nonprescription medicines to manage potential interactions.


Q: Can older adults use Palladone safely?

Regulatory information indicates that the elderly or those who are frail are advised to use the medicine with caution. Older adults may be at an increased risk of severe respiratory depression, especially when first starting treatment. Official guidance indicates that a reduced initial dose may be required for these patient groups to mitigate this risk.


Q: Is Palladone used to treat nerve pain?

Palladone is officially indicated for the management of moderate-to-severe pain in situations where an opioid analgesic is deemed appropriate. Regulatory documents do not explicitly restrict the drug's use to certain types of pain, nor do they specifically promote its use for neuropathic pain (nerve pain).


Q: Will Palladone show up on a standard drug test?

Yes, the active ingredient, hydromorphone, can be detected in biological samples used for drug screening. Toxicology resources indicate that the presence of hydromorphone above a certain level usually demonstrates exposure to the medicine in the two to three days before the sample was collected.


Q: Is Palladone available as a generic medicine?

Palladone is a brand name for hydromorphone. The Food and Drug Administration (FDA) has approved generic versions of hydromorphone in various forms, including oral tablets, oral solution, and injection.


Q: Can Palladone affect hormone levels or fertility?

Long-term use of opioid medicines may be associated with a decrease in sex hormone levels, a condition known as hypogonadism. Official drug safety communications indicate that this may cause symptoms such as reduced interest in sex, impotence, or infertility in both male and female patients.


Q: Is Palladone used in hospice or palliative care settings?

Hydromorphone is a powerful opioid widely utilized for pain control in settings such as hospice and palliative care. Its use is supported for managing moderate to severe pain and for treating dyspnea (shortness of breath) in patients requiring comprehensive symptom management.


Q: Does Palladone cause issues with sleeping or insomnia?

Official adverse reaction lists indicate that hydromorphone frequently causes drowsiness and can be associated with sleep-related breathing problems, such as sleep apnea. Insomnia, which is difficulty sleeping, is not typically listed as a common side effect of this medicine.


Q: What should a person do if they suspect an interaction with Palladone?

Official patient safety information advises individuals to consult with a physician or pharmacist before starting, stopping, or changing any medications while using Palladone. This action is noted in regulatory information as being necessary for the proper management of potential interactions, such as those with CNS depressants or alcohol.


Q: What should I do if I think I'm experiencing side effects?

If you experience any severe or life-threatening symptoms, such as difficulty breathing, severe dizziness, or fainting, official guidance directs that emergency medical services be called immediately. For less severe side effects, official labeling suggests informing the prescribing doctor if symptoms are persistent or concerning.

How should Palladone be stored and disposed of?

Storage and Disposal of Palladone

Storage of Palladone (hydromorphone hydrochloride) must strictly adhere to regulatory requirements to maintain its stability and prevent misuse.

Storage Requirement Conditions
Temperature Store at controlled room temperature, between 20°C and 25°C.
Protection Keep in a tightly closed container, protected from light and moisture.
Security Store in a safe place, out of the sight and reach of children, due to the risk of fatal accidental overdose and its status as a controlled substance.

Official Disposal Instructions

Unused or expired Palladone must be disposed of immediately. The preferred method is using an authorized drug take-back program. If this option is not available, official instructions mandate that the tablets be flushed down the toilet to rapidly remove the danger of accidental ingestion, as the product is listed by the FDA for immediate disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Palladone found in:

A-Z Index: